The Goldman Sachs Group Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $3.00

Definitive Healthcare (NASDAQ:DH) had its target price trimmed by The Goldman Sachs Group from $4.50 to $3.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other equities research analysts have also commented on the company. Barclays dropped their price target on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research note on Monday. Stephens started coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Definitive Healthcare currently has a consensus rating of “Hold” and an average target price of $5.35.

Definitive Healthcare Stock Performance

Definitive Healthcare stock opened at $2.63 on Tuesday. The firm has a market capitalization of $303.83 million, a P/E ratio of -0.85, a PEG ratio of 4.06 and a beta of 1.45. The stock has a fifty day moving average price of $4.52 and a 200 day moving average price of $4.44. Definitive Healthcare has a 52 week low of $2.58 and a 52 week high of $8.71. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The business had revenue of $62.29 million during the quarter, compared to analyst estimates of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. Equities research analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA lifted its holdings in Definitive Healthcare by 36.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock worth $27,058,000 after buying an additional 1,626,813 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Definitive Healthcare during the 3rd quarter worth approximately $512,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Definitive Healthcare by 34.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company’s stock worth $209,000 after buying an additional 12,946 shares during the last quarter. Barclays PLC lifted its holdings in Definitive Healthcare by 318.8% during the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock worth $366,000 after buying an additional 62,354 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Definitive Healthcare by 431.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company’s stock worth $993,000 after buying an additional 180,323 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.